Fabry's disease overview: Difference between revisions
Ghsanadgol (talk | contribs) No edit summary |
Ghsanadgol (talk | contribs) No edit summary |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Fabry's disease}} | {{Fabry's disease}} | ||
{{CMG}}; {{AE}} {{GhazalS}} | |||
==Overview== | |||
[[Fabry's disease]] (also known as [[alpha-galactosidase A deficiency]], [[ceramide trihexosidase deficiency]], [[Angiokeratoma corporis diffusum universale|angiokeratoma corporis diffusum]], Anderson Fabry disease) is an [[X-linked recessive]] inherited [[lysosomal storage disorder]]. | |||
==Historical Perspective== | |||
[[Fabry's disease]] is a rare inherited genetic condition that leads to the [[α-galactosidase A enzyme deficiency]] in individuals. [[Fabry's disease]] (or Anderson - Fabry disease) was first described separately by two physicians at the end of the 19th century. The feature and pathophysiology of the disease have been revealed through the years by various scientists. | |||
==Classification== | |||
[[Fabry's disease]] can be classified based on its different [[phenotypes]] or [[complications]]. Its different phenotypes are: classic and late-onset. The different complications involves: cardiac, renal, and neuropathic forms. | |||
==Pathophysiology== | |||
[[Genes]] involved in the pathogenesis of [[Fabry's disease]] include the [[GLA gene]], which codes the important enzyme of [[alpha-galactosidase]]. The absence or lack of this enzyme causes [[Gb3]] accumulation in different organs. The main pathological finding is detection of these inclusion in different cells with [[electron microscopies]]. | |||
==Causes== | |||
[[Fabry's disease]] is caused by a mutation in the GLA gene. | |||
==Differentiating Fabry's disease from Other Diseases== | |||
[[Fabry's disease]] is often misdiagnosed due to its rarity and wide range of non-specific clinical manifestations. Fabry's disease be differentiated from various kind of condition based on the symptoms and organ involvement. | |||
==Epidemiology and Demographics== | |||
[[Fabry's disease]] is a rare condition with a [[prevalence]] of approximately 6:100,000 to 0.8:100,000 in men. This disease mostly affects men and has no rational disparities. | |||
==Risk Factors== | |||
There are no established risk factors for Fabry's disease. | |||
==Screening== | |||
According to National society of Genetic Counselors, screening for [https://www.wikidoc.org/index.php/Fabry's%20disease Fabry's disease] in patient family member is recommended. The early [https://www.wikidoc.org/index.php/Prenatal prenatal] and [https://www.wikidoc.org/index.php/Newborn%20screening newborn screening] can be done by [https://www.wikidoc.org/index.php/%CE%91-Gal_A_enzyme α-Gal A enzyme] and ''[https://www.wikidoc.org/index.php/GLA_deficiency GLA]'' mutation analyses. Based on American Heart Failure society the [https://www.wikidoc.org/index.php/Fabry's%20disease Fabry's disease] screening should be done in males with unexplained [https://www.wikidoc.org/index.php/Cardiac%20hypertrophy cardiac hypertrophy]. | |||
==Natural History, Complications, and Prognosis== | |||
If [[Fabry's disease]] leaves untreated it can lead to [[end-stage renal disease]] (ESRD), [[cardiomyopathy]], and [[stroke]] which are the main causes of death in these patients. [[Enzyme replacement therapy]] (ERT) treatment has an important role in their life expectancy and disease complications. | |||
==Diagnosis== | |||
===History and Symptoms=== | |||
A positive history of [[angiokeratomas]], [[Neuropathies|peripheral neuropathies]], gradually decreased [[Sweating deficiency|sweating]], and [[gastrointestinal]] manifestations in childhood are suggestive of classic [[Fabry's disease]]. In the late-onset form of the disease [[neuropathic]] pain and [[gastrointestinal]] manifestation is not common and they may have organ-specific symptoms. | |||
===Physical Examination=== | |||
The presence of [[angiokeratomas]] on [[physical examination]] is highly suggestive of [[Fabry's disease]]. other physical examinations can be varied due to organ involvement. | |||
===Laboratory Findings=== | |||
A reduced concentration of serum [[Alpha-galactosidase A deficiency|Alpha-galactosidase A level]] or its activity is diagnostic of Fabry's disease. Other laboratory findings can vary due to organ involvement. | |||
===Electrocardiogram=== | |||
However the [[ECG]] patterns are not specific for Fabry's , it may be helpful in the diagnosis of [[Fabry's disease]] [[cardiac]] complications. | |||
== | ===CT scan=== | ||
[[CT scan]] can show different non-specific aspects of the [[brain]], [[lung]], and [[kidney]] involvement in [[Fabry's disease]]. | |||
===MRI=== | |||
[[MRI]] can play an important role in the diagnosis of the brain and cardiac complications of [[Fabry's disease]]. there are also some non-specific findings in renal involvement. | |||
===Echocardiography and ultrasound=== | |||
[[Echocardiography]] and [[Ultrasound|renal ultrasound]] can reveal the diagnostic pattern of [[Fabry's disease]] in these particular organs. | |||
===Other Imaging Findings=== | |||
There are no other imaging findings associated with Fabry's disease. | |||
===Other Diagnostic Studies=== | |||
There are no other diagnostic studies associated with Fabry's disease. | |||
==Treatment== | |||
===Medical Therapy=== | |||
The mainstay of therapy for [[Fabry's disease]] is enzyme replacement by [[Agalsidase alfa|Agalsidase]]<nowiki/>s. Other treatment is increasing the enzyme activity by [[Migalastat]]. There are also some general treatments for Fabry's disease complications. | |||
===Surgery=== | |||
[[Kidney transplantation]] can be a surgical option in certain [[Fabry's disease]] patients. | |||
==References== | ==References== | ||
{{reflist|2}} | |||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Needs english review]] | |||
[[Category:Medicine]] | |||
[[Category:Oncology]] | |||
[[Category:Gynecology]] | |||
[[Category:Up-To-Date]] | |||
Latest revision as of 10:23, 14 July 2022
|
Fabry's disease Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fabry's disease overview On the Web |
|
American Roentgen Ray Society Images of Fabry's disease overview |
|
Risk calculators and risk factors for Fabry's disease overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ghazal Sanadgol, M.D.[2]
Overview
Fabry's disease (also known as alpha-galactosidase A deficiency, ceramide trihexosidase deficiency, angiokeratoma corporis diffusum, Anderson Fabry disease) is an X-linked recessive inherited lysosomal storage disorder.
Historical Perspective
Fabry's disease is a rare inherited genetic condition that leads to the α-galactosidase A enzyme deficiency in individuals. Fabry's disease (or Anderson - Fabry disease) was first described separately by two physicians at the end of the 19th century. The feature and pathophysiology of the disease have been revealed through the years by various scientists.
Classification
Fabry's disease can be classified based on its different phenotypes or complications. Its different phenotypes are: classic and late-onset. The different complications involves: cardiac, renal, and neuropathic forms.
Pathophysiology
Genes involved in the pathogenesis of Fabry's disease include the GLA gene, which codes the important enzyme of alpha-galactosidase. The absence or lack of this enzyme causes Gb3 accumulation in different organs. The main pathological finding is detection of these inclusion in different cells with electron microscopies.
Causes
Fabry's disease is caused by a mutation in the GLA gene.
Differentiating Fabry's disease from Other Diseases
Fabry's disease is often misdiagnosed due to its rarity and wide range of non-specific clinical manifestations. Fabry's disease be differentiated from various kind of condition based on the symptoms and organ involvement.
Epidemiology and Demographics
Fabry's disease is a rare condition with a prevalence of approximately 6:100,000 to 0.8:100,000 in men. This disease mostly affects men and has no rational disparities.
Risk Factors
There are no established risk factors for Fabry's disease.
Screening
According to National society of Genetic Counselors, screening for Fabry's disease in patient family member is recommended. The early prenatal and newborn screening can be done by α-Gal A enzyme and GLA mutation analyses. Based on American Heart Failure society the Fabry's disease screening should be done in males with unexplained cardiac hypertrophy.
Natural History, Complications, and Prognosis
If Fabry's disease leaves untreated it can lead to end-stage renal disease (ESRD), cardiomyopathy, and stroke which are the main causes of death in these patients. Enzyme replacement therapy (ERT) treatment has an important role in their life expectancy and disease complications.
Diagnosis
History and Symptoms
A positive history of angiokeratomas, peripheral neuropathies, gradually decreased sweating, and gastrointestinal manifestations in childhood are suggestive of classic Fabry's disease. In the late-onset form of the disease neuropathic pain and gastrointestinal manifestation is not common and they may have organ-specific symptoms.
Physical Examination
The presence of angiokeratomas on physical examination is highly suggestive of Fabry's disease. other physical examinations can be varied due to organ involvement.
Laboratory Findings
A reduced concentration of serum Alpha-galactosidase A level or its activity is diagnostic of Fabry's disease. Other laboratory findings can vary due to organ involvement.
Electrocardiogram
However the ECG patterns are not specific for Fabry's , it may be helpful in the diagnosis of Fabry's disease cardiac complications.
CT scan
CT scan can show different non-specific aspects of the brain, lung, and kidney involvement in Fabry's disease.
MRI
MRI can play an important role in the diagnosis of the brain and cardiac complications of Fabry's disease. there are also some non-specific findings in renal involvement.
Echocardiography and ultrasound
Echocardiography and renal ultrasound can reveal the diagnostic pattern of Fabry's disease in these particular organs.
Other Imaging Findings
There are no other imaging findings associated with Fabry's disease.
Other Diagnostic Studies
There are no other diagnostic studies associated with Fabry's disease.
Treatment
Medical Therapy
The mainstay of therapy for Fabry's disease is enzyme replacement by Agalsidases. Other treatment is increasing the enzyme activity by Migalastat. There are also some general treatments for Fabry's disease complications.
Surgery
Kidney transplantation can be a surgical option in certain Fabry's disease patients.